

**Drugs and Therapeutics (D & T) Committee  
Meeting Results  
September 13, 2017**

<b>Drug Name</b>	<b>Review Type</b>	<b>Committee Recommendation</b>	<b>Prior Approval Status – Final Determination</b>
Emflaza	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Mavyret	New Drug Initial Review	Table final decision pending full class review.	Non-preferred requires PA
Egrifta	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Repatha	New Drug Appeal	Table discussion pending next D&T Committee meeting	Non-preferred requires PA